ESMO: Lynparza, Zejula Continue Rivalry With Long-Term Ovarian Maintenance Data
AstraZeneca/Merck’s Lynparza showed an OS benefit in first-line maintenance of ovarian cancer, but while data for Zejula were less mature, the GSK drug targets a broader population.
You may also be interested in...
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.
The AUGMENT-101 study showed a strong response rate among acute leukemia patients who historically have a poor prognosis.